PR Domain Containing 16 (PRDM16) (Middle Region) Peptide
PRDM16
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all PRDM16 products
- PRDM16 (PR Domain Containing 16 (PRDM16))
- Protein Region
- Middle Region
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- SAPASGEEQP LDLSIGSRAR ASQNGGGREP RKNHVYGERK LGAGEGLPQV
- Characteristics
- This is a synthetic peptide designed for use in combination with anti- PRDM16 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- PRDM16 (PR Domain Containing 16 (PRDM16))
- Background
-
The reciprocal translocation t(1,3)(p36,q21) occurs in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This gene is located near the 1p36.3 breakpoint and has been shown to be specifically expressed in the t(1:3)(p36,q21)-positive MDS/AML. The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal PR domain. The translocation results in the overexpression of a truncated version of this protein that lacks the PR domain, which may play an important role in the pathogenesis of MDS and AML. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
Alias Symbols: MEL1, LVNC8, PFM13, CMD1LL
Protein Size: 1092 - Gene ID
- 63976
- NCBI Accession
- NM_022114, NP_071397
-
You are here:
